A Phase 1, Open-Label Fixed-Sequence 2-Period Crossover Study Of Palbociclib In Healthy Subjects To Investigate The Potential Effect Of Antacid Treatment On The Pharmacokinetics Of A Single Oral Dose Administered Under Fasted Conditions
Phase of Trial: Phase I
Latest Information Update: 01 Jan 2017
Price : $35 *
At a glance
- Drugs Palbociclib (Primary) ; Rabeprazole
- Indications Breast cancer; Colorectal cancer; Gastro-oesophageal reflux; Glioblastoma; Liposarcoma; Mantle-cell lymphoma; Peptic ulcer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
- 01 Dec 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Sep 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 09 Aug 2013 New trial record